THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2016

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2016

MARKETPLACE

New pathology lab products and industry news

Home » Top news

Quest acquires two Texas labs

June 15, 2017—Quest Diagnostics has signed definitive agreements to acquire Med Fusion and Clear Point, both based in Lewisville, Texas, with the aim to establish a center of excellence providing diagnostic services to aid the detection and management of cancer for oncologists and patients nationwide. Baylor Scott & White Health; the US Oncology Network (the Network), supported by McKesson Specialty Health; Texas Oncology; and Pathologists Bio-Medical Laboratories are co-owners of one or both businesses.

Once the transaction is complete, which is expected in the third quarter of this year and subject to regulatory approvals, Quest will become a preferred provider of oncology diagnostics for the Network, including Texas Oncology. The Network consists of more than 400 locations in the U.S. with more than 1,400 independent, community-based physicians. Quest will provide genomic and pathology testing, such as tumor sequencing; inherited genetic testing, such as for BRCA breast cancer screening, will not be part of a preferred provider relationship.

Quest will also be a preferred provider of a full range of inpatient and outpatient diagnostic services for 12 Baylor Scott & White Health hospitals in North Texas. Quest and PBM will also have a preferred provider relationship for several services.

McKesson Specialty Health, with the Network and Texas Oncology, plan to collaborate with Quest on the development of standardized, evidence-based services for guiding treatment decisions within the electronic patient record and care plan workflow, building off a model spearheaded by Med Fusion.

More top news

Print Friendly, PDF & Email
Tags:

X